A meta-analysis of 14 RCTs, including 6428 patients with HFpEF or MI with preserved ejection fraction, found that MR antagonist therapy led to a reduction in heart failure hospitalizations by 17%, improved diastolic function, reversed cardiac remodelling, and enhanced quality of life, but did not reduce all-cause mortality [67]. This evidence concerns the gene NR3C2 and heart failure.